In the age of COVID-19 and social-distancing, diagnostic companies have to provide more than just assays. CareDx has tapped into this idea and launched a solution that will enable remote home-based monitoring of transplant patients.
The South San Francisco, CA-based company said its RemoTraC can help reduce visits to busy labs and hospitals and that immunosuppressed transplant patients at the highest risk during the COVID-19 pandemic can limit their potential exposure.
Typically, transplant patients require frequent blood tests which normally require in-person visits to draw sites at labs or hospitals.
“Because of our digital solutions, we’re able to monitor these patients on a very regular interval because many times the surveillance isn’t happening at the transplant center with the frequency that is needed,” Peter Maag, Chairman and CEO of CareDx, told MD+DI. “We have a care team that makes sure these patients are continuously being followed up.”
He added, “the new feature is that we can do this with mobile phlebotomy. On the one hand, it’s non-invasive technology, on the other hand, its technology of caring for those patients longitudinally after implantation.”
RemoTraC will be offered to all patients who want their transplant monitoring lab tests to be drawn from the comfort of their home by trained mobile phlebotomists. The device is a remote home-based blood draw solution using mobile phlebotomy for AlloSure and AlloMap surveillance tests, as well as for other standard monitoring tests.
In addition to launching RemoTrac, CareDx is also supporting the patients by running a COVID-19 transplant registry through its OttrCare platform called C19TxR. With the COVID-19 pandemic, there is limited data on the impact on immunosuppressed transplant recipients who acquire the disease.
The registry site will be free to use, open access, and web-based, with a real-time analytics dashboard for users to quickly engage in best practices for COVID-positive transplant patient management.
“International transplant clinicians are encouraged to submit patients through the brief data submission. These data will be invaluable in identifying potential strategies to mitigate the impact of COVID-19 in solid organ transplant recipients,” David Axelrod, MD MBA, Chairman Standards Committee American Society of Transplant Surgeons, said in a release.